CEO Brian Moynihan said he knows some employees will leave before reaping the health benefits.
By
Alice Tecotzky
You're currently following this author!
Want to unfollow? Unsubscribe via the link in your email.
Brian Moynihan said Bank of America spends more than $250,000 on GLP-1s.
Bank of America spending $250M a year on GLP-1 weight loss drugs
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
This bank spends $250M annually on weight-loss drugs for employees
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investm
Bank of America is splashing out $250 million a year on weight loss drugs for its staff: ‘We see a great impact on employees,’ CEO says | Fortune
Major bank spends $250 million a year on GLP-1 drugs for its employees, CEO says
Bank of America defiende gastar 250 millones al año en fármacos contra la obesidad para sus trabajadores (y no es el único)
As companies in America face rising health costs, Starbucks ends employee benefits' coverage for these medicines
CEO Brian Moynihan says GLP-1 medications now account for roughly 13% of the bank's total annual healthcare spending
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per…
Bank of America allocates over $250 million annually for GLP-1 weight loss drugs, CEO Brian Moynihan revealed, emphasizing the…
Bank of America spends over $250 million yearly on GLP-1 drugs, with CEO Brian Moynihan calling it a smart investment.
Weight-loss drugs are becoming a popular perk, with almost a third of workers saying they’d even switch jobs for it. Bank of…
GLP-1 drugs for weight loss are on the rise, with 11 percent of Americans saying they take one in a recent poll
